$0.75
-0.00 (-0.45%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where JSPR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional
Held by 4 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, Qube Research & Technologies Ltd) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsNCT06736262To evaluate the safety and tolerability of briquilimabOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns. | Drug: Briquilimab | Urticaria Chronic | 67 | 2026-07-21actual | 2026-08-06 |
| Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)NCT06162728Evaluate the safety and tolerability of briquilimabRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: Briquilimab · Other: Placebo | Chronic Spontaneous Urticaria | 87 | 2026-07-08actual | 2026-08-06 |
| A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic AsthmaNCT06592768To evaluate the safety and tolerability of briquilimab in mild-to-moderate asthmatic participantsRandomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns. | Drug: Briquilimab · Other: Placebo Comparator | Allergic Asthma | 17 | 2025-08-11actual | 2025-09-16 |
| A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- AntihistaminesNCT06353971Incidence and severity of treatment emergent AEs/SAEs [safety and tolerability] of a single dose of briquilimab in patients with ColdU or SD who remain symptomatic despite the use of H1 antihistamines.Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Enrollment was completed and primary efficacy endpoint was completed. Study was terminated before safety follow up was completed due to changes in company priorities and not related to safety concerns | Drug: Briquilimab | Chronic Inducible Urticaria | 27 | 2025-07-31actual | 2025-10-08 |
| JSP191 Antibody Targeting Conditioning in SCID PatientsNCT02963064Phase 1: Safety and tolerability of JSP191 as conditioning therapy in SCID patients undergoing HCT: adverse eventsOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns. | Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191) | SCID | 23 | 2025-07-07actual | 2025-07-28 |
| JSP191 (briquilimab) in Subjects with LR-MDSNCT05903274Safety and tolerability of JSP191Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The study was terminated due to a lack of improvement in clinical efficacy outcomes. | Drug: JSP191 | Lower-risk Myelodysplastic Syndrome | 6 | 2024-10-21actual | 2025-02-27 |
| JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell TransplantationNCT04429191The number of subjects experiencing adverse events and serious adverse events will be assessed.Open-label · Treatment | Phase 1 | Unknown status | Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191) | MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML | 40 | 2023-10-15 | 2021-06-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19